Soleno Therapeutics (SLNO) Finished Goods (2025 - 2026)

Soleno Therapeutics' (SLNO) quarterly Finished Goods came in at $7.2 million in Q1 2026, up 19.89% on a QoQ basis from $6.0 million in Q4 2025.

Soleno Therapeutics (SLNO) Finished Goods (2025 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 2 years of Finished Goods data on file, last reported at $7.2 million in Q1 2026.

On a quarterly basis, Finished Goods changed N/A year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.0 million, changed N/A from the prior year.
Finished Goods for Q1 2026 stood at $7.2 million, up from $6.0 million in the prior quarter.
Over the last five years, Finished Goods for SLNO reached as high as $7.2 million in Q1 2026 and fell as low as $262000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn

Download Data